Insufficient scRNA-seq data for expression of PSG9 at single-cell level.
Insufficient scRNA-seq data for expression of PSG9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 64% | 6.12 | 1159 / 1809 | 4% | 0.14 | 18 / 472 |
kidney | 54% | 3.42 | 48 / 89 | 7% | 0.54 | 61 / 901 |
breast | 50% | 1.51 | 228 / 459 | 3% | 0.15 | 28 / 1118 |
pancreas | 52% | 4.51 | 170 / 328 | 0% | 0 | 0 / 178 |
adipose | 43% | 1.26 | 517 / 1204 | 0% | 0 | 0 / 0 |
brain | 39% | 1.39 | 1037 / 2642 | 0% | 0 | 0 / 705 |
prostate | 36% | 1.29 | 88 / 245 | 0% | 0 | 0 / 502 |
uterus | 27% | 1.22 | 46 / 170 | 0% | 0.03 | 2 / 459 |
esophagus | 20% | 0.49 | 282 / 1445 | 2% | 0.05 | 3 / 183 |
ovary | 21% | 0.34 | 37 / 180 | 0% | 0 | 0 / 430 |
adrenal gland | 18% | 0.39 | 47 / 258 | 1% | 0.03 | 3 / 230 |
thymus | 16% | 0.35 | 106 / 653 | 0% | 0.00 | 1 / 605 |
bladder | 14% | 0.43 | 3 / 21 | 2% | 0.07 | 8 / 504 |
peripheral blood | 13% | 0.27 | 124 / 929 | 0% | 0 | 0 / 0 |
liver | 11% | 0.26 | 25 / 226 | 1% | 0.04 | 5 / 406 |
spleen | 12% | 0.26 | 29 / 241 | 0% | 0 | 0 / 0 |
stomach | 11% | 0.26 | 39 / 359 | 1% | 0.06 | 3 / 286 |
lung | 11% | 0.21 | 62 / 578 | 1% | 0.06 | 13 / 1155 |
intestine | 11% | 0.27 | 107 / 966 | 1% | 0.02 | 4 / 527 |
heart | 9% | 0.18 | 78 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 8% | 0.13 | 105 / 1335 | 0% | 0 | 0 / 0 |
muscle | 8% | 0.19 | 62 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 6% | 0.19 | 5 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_1900016 | Biological process | negative regulation of cytokine production involved in inflammatory response |
GO_0002461 | Biological process | tolerance induction dependent upon immune response |
GO_0002682 | Biological process | regulation of immune system process |
GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
GO_0045589 | Biological process | regulation of regulatory T cell differentiation |
GO_0007565 | Biological process | female pregnancy |
GO_0002774 | Biological process | Fc receptor mediated inhibitory signaling pathway |
GO_0070021 | Cellular component | transforming growth factor beta ligand-receptor complex |
GO_0009986 | Cellular component | cell surface |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_1990782 | Molecular function | protein tyrosine kinase binding |
Gene name | PSG9 |
Protein name | Pregnancy specific beta-1-glycoprotein 9 Pregnancy-specific beta-1-glycoprotein 9 (PS-beta-G-9) (PSBG-9) (Pregnancy-specific glycoprotein 9) (PS34) (Pregnancy-specific beta-1 glycoprotein B) (PS-beta-B) (Pregnancy-specific beta-1-glycoprotein 11) (PS-beta-G-11) (PSBG-11) (Pregnancy-specific glycoprotein 11) (Pregnancy-specific glycoprotein 7) (PSG7) PSG9 protein |
Synonyms | hCG_1995680 PSG11 |
Description | FUNCTION: Binds to the small latent transforming growth factor-beta complex, consisting of the N-terminal TGFB1 latency-associated peptide (LAP) and the mature form of TGFB1, thereby leading to the activation of TGFB1 . The activation of TGFB1 leads to stimulation of naive CD4(+) T-cells to increase FoxP3 expression and to an increase in the number of FoxP3(+) regulatory T-cells . Induces the differentiation of a suppressive CD4(+)LAP(+)FoxP3(-) T-cell subset . Induces the secretion of TGFB1 in macrophages, but not in activated CD4(+) T-cells . May reduce the expression of several pro-inflammatory cytokines and chemokines by CD4(+) T-cells, including IL2 and IL6 . . |
Accessions | G3XAA7 Q05DN5 ENST00000244293.11 [Q00887-2] M0R0E4 ENST00000593948.5 ENST00000621109.4 ENST00000596730.1 E7EW65 ENST00000291752.9 H7C1I4 Q00887 A0A087WYK1 ENST00000443718.7 ENST00000270077.8 [Q00887-1] Q6LEU7 ENST00000418820.6 M0R0U8 |